Abbvie Inc

-0.18 (-0.15%)
4:00:00 PM EDT: $116.39 -0.03 (-0.03%)
Products, Regulatory

Abbvie's Rinvoq Meets Primary And All Ranked Secondary Endpoints In Ulcerative Colitis study

Published: 12/09/2020 13:55 GMT
Abbvie Inc (ABBV) - Upadacitinib (rinvoq™) Meets Primary and All Ranked Secondary Endpoints in First Phase 3 Induction Study in Ulcerative Colitis.
Abbvie - Significantly More Upadacitinib-treated Patients Achieved Clinical Remission at Week 8 Versus Placebo.
Abbvie Inc - Safety Results in Study Were Consistent With Known Profile of Upadacitinib, With No New Safety Risks Observed.